Related Experiment Video
Updated: Jul 12, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
Abdominal massage alleviates IBS-D by modulating the gut microbiota and suppressing the LPS/TLR4/NF-κB/MLCK pathway
Huanan Li1,2, Xiaoyu Wang3,4, Lianjun Yin5
1Department of Tuina, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background:
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common functional gastrointestinal disorder with complex and incompletely understood pathophysiology. This study aimed to investigate the therapeutic effects and underlying mechanisms of abdominal massage on diarrhea-predominant IBS-D using a rat model.
Methods:
IBS-D was induced in Sprague-Dawley rats through a combination of maternal separation and chronic stress. The experimental interventions consisted of abdominal massage and fecal microbiota transplantation (FMT) using donor microbiota obtained from IBS-D + abdominal massage rats. Assessments included fecal moisture content (FMC), Bristol stool scores, visceral hypersensitivity, intestinal motility, open field test, gut microbiota, short-chain fatty acids (SCFAs), inflammatory markers (LPS, TLR4/MyD88/NF-κB pathway), and intestinal barrier integrity (TEM, tight junction proteins, FITC-dextran permeability).
Results:
Abdominal massage significantly improved diarrheal symptoms, visceral hypersensitivity, gastrointestinal motility, and anxiety-like behaviors in IBS-D rats. It restored gut microbiota diversity, reduced SCFA levels, and suppressed the TLR4/MyD88/NF-κB pathway, leading to decreased pro-inflammatory cytokines and LPS levels. FMT replicated these effects, suggesting the role of gut microbiota modulation. Moreover, abdominal massage also ameliorated barrier dysfunction in IBS-D rats by restoring ultrastructure, modulating MLCK and junctional proteins, and reducing macromolecular permeability.
Conclusion:
Abdominal massage alleviates IBS-D symptoms by modulating gut microbiota, inhibiting the TLR4/MyD88/NF-κB/MLCK signaling pathway, reducing inflammation, and restoring intestinal barrier function. These findings support its potential as a non-invasive therapeutic strategy for IBS-D.
Related Concept Videos
Irritable Bowel Syndrome
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Irritable Bowel Syndrome III: Medical and Nursing Management
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

